Purdue slashes work force as generic OxyContin gets green light

With a generic version of OxyContin on the way, Purdue Pharma says it will be forced to lay off more than 800 workers, or 38 percent of its employees. OxyContin accounts for 75 percent of the company's revenues. Among those affected are 290 employees at the company's headquarters in Stamford, Connecticut. The company has other painkillers in the pipeline and is also developing a generic version of OxyContin.

- read this report from the San Diego Union-Tribune for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.